Objective-The renin-angiotensin-aldosterone system (RAS) plays a central role in atherosclerosis. To investigate the effects of a direct renin inhibitor aliskiren on vascular inflammation, we conducted leukocyte adhesion assays in vivo and in vitro using a novel real-time imaging system. Methods and Results-Aliskiren (10 mg/kg/d) or PBS was administered to C57BL/6 mice (6 -7 weeks of age; Oriental Yeast, Tokyo, Japan) for 2 weeks via an osmotic pump. Blood pressure was not significantly changed in the 2 groups throughout the experimental period. A perivascular cuff injury was then introduced to the femoral artery and real-time intravital microscopic observation was conducted 24 hours after injury. The number of adherent leukocytes was elevated in the injured mice without aliskiren (43.8Ϯ9.3/10 Ϫ2 mm 2 ), whereas that was significantly reduced in the mice with aliskiren (18.4Ϯ4.4, PϽ0.05). Treatment of human umbilical vein endothelial cells (HUVECs) with aliskiren significantly reduced the adhesion of THP-1 cells to TNF-␣-activated HUVECs (PϽ0.05). Interestingly, TNF-␣-induced renin activity and angiotensin II production in HUVECs were also blunted by aliskiren. Furthermore, exogenous renin and angiotensin II abrogated the aliskiren-mediated reduction of THP-1 cell adhesion to HUVECs. Conclusions-Our in vivo and in vitro findings indicate a pivotal role for renin inhibition in vascular inflammation independent of blood pressure.
T he renin-angiotensin-aldosterone system (RAS) has been recognized as one of the key mechanisms involved in various vascular diseases including atherosclerosis. [1] [2] [3] Recent reports have also demonstrated that production of RAS in extrarenal tissues exerts critical biological effects, 4 -7 whereas regulation of local RAS contributes to the pathophysiological condition of endothelial cells and smooth muscle cells. 8, 9 Therefore, modulation of local as well as systemic RAS has emerged as a therapeutic concept for cardiovascular diseases.
Angiotensin (Ang) II, a potent vasoconstrictive peptide, plays a crucial role in atherosclerosis via local activation of mitogen-activated protein kinases (MAPK). In addition, we previously found that Ang II-related oxidative stress in leukocytes induces leukocyte recruitment in vivo. 10 However, the continued presence of other bioactive angiotensin-related peptides has made it difficult to elucidate the contributions of Ang II in these processes.
Renin, a rate-limiting enzyme for Ang II formation, exerts various inflammatory reactions, including activation of thrombogenic molecules 11 and intracellular signaling proteins independent of local Ang II, 12 which are mediated via the recently characterized renin receptor (RR). 13 Recently aliskiren, a direct renin inhibitor, has been shown to modulate vascular diseases such as hypertension, 14 experimental atherosclerosis, 15 and diabetic nephropathy 16 via RAS dependent or independent pathway. Although local RAS are important in those processes, the importance of renin inhibition in vascular inflammation has not been elucidated.
In the present study, we focused on the effects of aliskiren on leukocyte-endothelial interaction, a crucial step in vascular inflammation. We used intravital microscopy (IVM) to visualize acute phase leukocyte recruitment in mouse femoral arteries injured by perivascular cuff placement and also examined the responsible molecular mechanisms in vitro.
Materials and Methods
The Materials and Methods section detailing the techniques and procedures used in the present study is available as an supplemental materials (available online at http://atvb.ahajournals.org).
In Vivo Experiments
Aliskiren diluted in PBS or PBS alone was administered to C57BL/6 mice via an osmotic pump for 2 weeks. On day 13, a perivascular cuff was placed on the right femoral artery, and on day 14, the mice were injected via the left femoral vein with fluorescent labeled leukocytes. Immediately after the injection, the injured femoral artery was examined with an epifluorescent microscope and observed endothelial-leukocyte interactions images captured via an ultrasensitive camera.
Adhesion Assay Under Flow
Human umbilical vein endothelial cells (HUVECs) were stimulated with or without tumor necrosis factor ␣ (TNF-␣) and aliskiren on coverslips, then positioned in a flow chamber. THP-1 cells were perfused and drawn through the chamber at a controlled flow rate to generate a shear stress.
Western Blot Analysis and Quantitative RT-PCR Analysis
Lysate or mRNA was prepared from HUVECs in vitro or injured specimen in vivo and conducted after immunobloting or RT-PCR analysis.
Reactive Oxidative Stress Generation Analysis
HUVECs, stimulated with TNF-␣ and aliskiren were incubated with reactive oxidative stress (ROS)-detecting probe, CM-H 2 DCFDA, according to the manufacturers' protocol. Fluorescence intensity was evaluated using FACS caliber and CellQuest software.
Results

Aliskiren Reduced Leukocyte Recruitment After Injury In Vivo
To examine the antiinflammatory effects of aliskiren in vivo, we administered PBS or aliskiren at a dose of 3, 10, 25, or 50 mg/kg/d to C57BL/6 mice for 2 weeks. As shown in supplemental Figure I , treatment with aliskiren at 25 or 50 mg/kg/d significantly decreased blood pressure after 2 weeks. In contrast, lower doses, such as 3 and 10 mg/kg/d, did not alter blood pressure. Heart rate and body weight were not significantly altered among the groups during the 2-week experimental period (data not shown).
A perivascular cuff was placed on the femoral artery of mice on day 13 of PBS or aliskiren treatment and IVM observations were performed the following day. The representative snapshots ( Figure 1A through 1C) and video images (supplemental Movie) revealed that treatment with aliskiren reduced leukocyte recruitment to the injured arteries. Furthermore, image analysis ( Figure 1D ) showed that cuff placement significantly increased the number of adherent leukocytes (43.8Ϯ9.3/10 Ϫ2 mm 2 ), which was dose-dependently reduced by aliskiren. To separate the effect of aliskiren on blood pressure from that on inflammation, we used a lower dose (10 mg/kg/d) in the following experiments. We found that plasma renin activity and Ang II concentration were significantly decreased after aliskiren administration, which confirmed its efficacy in mice under the present study conditions (supplemental Figure II ).
Aliskiren Reduced Leukocyte-Endothelial Interaction In Vitro
To explore the molecular mechanisms of the antiadhesive action of aliskiren, we conducted a leukocyte-endothelial adhesion assay in vitro under a flow condition. Following our finding of TNF-␣ upregulation in the injured arteries (supplemental Figure III ), we stimulated HUVECs with TNF-␣ to mimic that effect in vitro. TNF-␣-induced THP-1 adhesion to HUVECs was significantly reduced by aliskiren in a dosedependent manner ( Figure 2A ) and reached a plateau after 4 hours ( Figure 2B ). In addition, Western blotting ( Figure 3A ) and real-time PCR (supplemental Figure IV) analyses revealed that TNF-␣-induced upregulation of E-selectin, ICAM-1, and VCAM-1 in HUVECs was attenuated by aliskiren, as was TNF-␣-induced activation of ERK, JNK, p-38 ( Figure 3B ) and NF-B (supplemental Figure VA) . Considering the relatively short time course of TNF-␣ stimulation (0.5 hour), the antiinflammatory effects of aliskiren may involve an RAS-independent signaling pathway. Thus, we compared the effects of aliskiren and an angiotensin receptor blocker (ARB), valsartan, as well as their combination. Aliskiren, but not valsartan, reduced JNK activation at 0.5 hour after TNF-␣-stimulation ( Figure 3C ). In contrast, aliskiren and valsartan equally reduced JNK activation after 4 hours. A combination of both reduced JNK activation at 0.5 hour to a level comparable to aliskiren, and at 4 hours to a level comparable to aliskiren and valsartan administered separately.
Aliskiren Reduced Renin-and Ang II-Dependent Inflammation In Vitro
We also evaluated the involvement of RAS in vitro. First, we measured renin activity and Ang II concentration in the culture medium of HUVECs. TNF-␣ increased local renin activity and Ang II production in the medium, both of which were decreased by aliskiren (supplemental Figure VI) . In contrast, the expression and activity of angiotensin converting enzyme (ACE) in HUVECs were not changed by TNF-␣ or aliskiren (supplemental Figures VII and VIII) . Because local RAS has been shown to play a role in vascular inflammation, we investigated whether the antiadhesive effect of aliskiren is mediated through inhibition of local RAS. Though exogenous renin and Ang II did not enhance THP-1 adhesion to TNF-␣-activated HUVECs, they restored aliskiren-mediated antiadhesive effects (supplemental Figure IXA) . Further, they were able to enhance THP-1 adhesion to minimally activated HUVECs (TNF-␣ at 0.1 ng/mL; supplemental Figure IXB) . Exogenous renin enhanced expressions of E-selectin, ICAM-1, and VCAM-1 ( Figure 4A ). It also restored aliskiren-mediated downregulation of adhesion molecules and inactivation of ERK, JNK, p38 ( Figure 4B ), and NF-B (supplemental Figure VB) .
Aliskiren Attenuated TNF-␣-Induced Oxidative Stress in HUVECs
To investigate the potential modulation of oxidative stress by aliskiren, the amount of oxidative stress was evaluated by examining the fluorescent intensity of CM-H 2 DCFDA in HUVECs by flow cytometry. Aliskiren inhibited TNF-␣-mediated oxidative stress ( Figure 5A and supplemental Figure X ) along with a reduction in TNF-␣-induced gp91 phox expression, a component of NADPH oxidase in HUVECs ( Figure 5B ). Furthermore, TNF-␣-mediated reduction of eNOS expression was recovered by aliskiren ( Figure 5C ). 
Aliskiren Stabilized Local Inflammation In Vivo
To explore the molecular link between renin inhibition and inflammation in vivo, we examined the expressions of adhesion molecules and representative signaling molecules, such as MAPK and NF-B, in the injured artery specimens. As shown in Figure 6A and 6B, perivascular cuff injury induced upregulation of E-selectin, ICAM-1, VCAM-1, and gp91 phox in the femoral arteries, which was reduced by treatment with aliskiren. Moreover, perivascular injury also activated the expressions of ERK, JNK, p38, and NF-B, which were attenuated by aliskiren ( Figure 6C and supplemental Figure  VC ). In addition, aliskiren reduced and increased eNOS expression in the injured arteries ( Figure 6D ), which was similar to our finding in vitro.
Discussion
Initiation of vascular disorders contains an inflammatory component characterized by leukocyte-endothelial interaction, in which orchestration of various adhesion molecules regulates the entire process. Herein, we focused on the effects of direct renin inhibition by aliskiren on leukocyte-endothelial interaction in vivo and in vitro.
Our results demonstrated that renin inhibition by aliskiren significantly reduced the number of leukocytes that adhered to cuff-injured femoral arteries in mice. Polyethylene cuff placement around the femoral artery has been shown to induce vascular inflammation accompanied by vascular remodeling. 17, 18 Although proliferation of smooth muscle cells and neointimal formation has been repeatedly documented in studies that used this injury model, acute phase vascular inflammation such as leukocyte recruitment to the injured artery has not been demonstrated. In the present study, we confirmed that perivascular cuff placement significantly induces leukocyte adhesion in the femoral artery. To our knowledge, this is the first real-time observation of leukocyte recruitment after perivascular injury in vivo as well as its blockade by renin inhibition. A reduction in leukocyte recruitment in vivo after aliskiren administration was achieved at a dose that showed no significant changes in blood pressure. Moreover, our in vitro experiments were conducted with cultured endothelial cells that were not exposed to high atmospheric pressure. Therefore, the observed effects of aliskiren were not a direct consequence of its ability to lower blood pressure. In addition, we observed that aliskiren reduced vascular remodeling at 28 weeks after cuff injury (supplemental Figure XI) , which confirmed the antiatherosclerotic effect of renin inhibition. Previous studies including ours have suggested a dominant role for adhesion molecules, including ICAM-1, VCAM-1, and E-selectin, in vascular inflammation. 19 -21 In the present study, we observed upregulation of these adhesion molecules in the injured arteries, each of which was reduced by aliskiren. We also documented the involvement of ERK, JNK, p38, and NF-B-dependent pathway in injury-induced leukocyte recruitment in vivo. Moreover, the cuff injury caused downregulation of eNOS expression and upregulation of gp91 phox in the injured arteries. These results show a causative role for oxidative stress and its stabilization by aliskiren in the present experimental model. Recent studies have suggested that Ang II induces inflammation and atherosclerosis via local activation of ERK, 22, 23 JNK, 24 and p38. 25 In addition, oxidative stress induced by Ang II causes activation of NF-B 26 and subsequent induction of E-selectin, 27 ICAM-1, 28 and VCAM-1. 29 Although the precise mechanisms are unclear at present, reduction in oxidative stress and stabilization of MAPK and NF-B may play dominant roles in aliskiren-mediated antiinflammatory effects in vivo. Exogenous renin and Ang II cancelled antiinflammatory actions of aliskiren including expressions of adhesion molecules, activation of MAPK and NFKB, and generation of ROS in activated HUVECs. Moreover, we observed that renin and Ang II enhanced THP-1 adhesion to minimally activated HUVECs with TNF-␣ at 0.1 ng/mL (supplemental Figure  IXB) . These results suggest that a magnitude of HUVEC stimulation by renin and Ang II is smaller than that by TNF-␣ at 1 ng/mL. Thus exogenous renin and Ang II failed to enhance THP-1 adhesion to HUVECs activated with 1 ng/mL TNF-␣. Interestingly, the inhibitory effects of aliskiren on MAPK and NF-B became apparent at 0.5 hour after TNF-␣ stimulation. Because TNF-␣ treatment increased Ang II production within 4 hours after stimulation (supplemental Figure XII) , aliskiren may directly block TNF-␣-dependent signaling in the absence of an Ang II-mediated RAS pathway. In fact, we confirmed that an ARB failed to inhibit JNK activation at 0.5 hour after TNF-␣ activation ( Figure 3C ). In contrast, both aliskiren and the ARB reduced JNK activation at 4 hours after activation of TNF-␣. Therefore, we speculate that aliskiren not only reduces the activity of the local RAS dependent pathway, but also directly inhibits TNF-␣-dependent inflammation in the absence of RAS (see supplemental Figure XIII ). This supports the notion of combined effects of an ARB and aliskiren in hypertension and atherosclerosis via modulation of RAS-dependent and -independent pathways. Recent reports have pointed out a potential role for RR in RAS-independent signaling by renin. 11, 13, 30 In addition, Feldman et al recently described the involvement of RR in aliskiren-mediated beneficial effects in diabetic nephropathy rat. 16 The contribution of an RR-dependent pathway in aliskiren-mediated modulation of vascular inflammation requires further investigation.
As previously reported, 31 leukocyte adhesion accelerates MAPK, NF-B, and ROS generation in leukocytes, leading to the development of a viscous cycle of inflammation. Thus, we consider that aliskiren may exert a clinical advantage by blocking exaggerated inflammation after vascular injury via modulation of the inflammatory cascade in leukocytes. In fact, recent studies have reported effects of RAS inhibition in monocytes. 32, 33 We intend to focus on the potential effects of aliskiren on leukocytes in a future investigation.
Blockade of renin has a potential advantage over inhibition of the angiotensin receptor or ACE, because aliskiren is able to block the synthesis of all angiotensin peptides and prevents a compensatory increase in renin activity. 34 -36 A combination of those to strongly inhibit the RAS cascade may further improve the stabilization of vascular inflammation.
Conclusion
Renin inhibition by aliskiren profoundly reduced leukocyte recruitment in perivascular cuff injury-induced acute vascular inflammation independent of blood pressure. The underlying mechanisms seemed to involve a reduction in adhesion molecules, MAPK, and NF-B via RAS-dependent andindependent pathways. 
